GET DAILY SIGNALSWhy Is MDxHealth (MDXH) Stock Down -7.6% Today?
Key Takeaways
- Shares of MDXH fell roughly 7.6% in early Monday trading, extending Friday's steep decline.
- The primary catalyst is the company's suspension of its full-year 2026 revenue guidance, announced alongside a disappointing preliminary third-quarter revenue figure.
- Analyst downgrades from Craig-Hallum and Lake Street compounded the selloff.
- Renewed liquidity and Nasdaq listing concerns are weighing on sentiment, with the stock trading well below $1.
- Traders are now watching the company's full third-quarter results and earnings call scheduled for November 12.
Opening Summary
MDxHealth SA (MDXH), a Nasdaq-listed urology-focused precision diagnostics company, saw its shares fall about 7.6% in early trading Monday, changing hands near $0.19 compared with Friday's closing price of roughly $0.21. The decline extends a punishing selloff that began last week, when the company suspended its full-year revenue outlook and reported preliminary third-quarter revenue well short of Wall Street expectations.
Guidance Suspension and Revenue Shortfall
The slide traces back to an October 15 announcement in which MDxHealth said it expects third-quarter 2026 revenue from continuing operations of approximately $22.7 million — essentially flat year over year — while suspending its full-year 2026 revenue guidance of $110 million to $115 million. The preliminary figure fell well below analyst consensus near $28.8 million.
Management attributed the shortfall to unexpected turnover within its sales force following the discontinuation of its Resolve mdx product earlier in the year. Chief Executive Officer Michael K. McGarrity acknowledged that the sales disruption "interrupted the progress" reported in the second quarter, though he maintained that underlying clinical demand and the company's long-term market opportunity remain intact. The announcement triggered a market reaction that sent MDXH shares down sharply on heavy volume.
Analyst Downgrades Compound the Pressure
The bearish sentiment was reinforced by a wave of analyst downgrades. Craig-Hallum cut MDXH from Buy to Hold, citing ongoing revenue struggles, the suspension of financial forecasts, and renewed concerns about liquidity. Lake Street likewise moved the stock to Hold from Buy, trimming its price target to $0.50 from $3 and arguing the company will be in "show-me territory" until it delivers a stronger fourth-quarter result.
The downgrades underscored a broader loss of confidence in the near-term trajectory, adding selling pressure to an already fragile equity.
Liquidity and Nasdaq Listing Concerns
Compounding the fundamental worries are persistent balance-sheet and listing risks. MDxHealth reported cash and cash equivalents of approximately $31.7 million as of September 30, 2026, and has previously disclosed Nasdaq notices regarding its sub-$1.00 bid price and its market value of listed securities. With shares now trading far below the $1.00 minimum bid-price threshold, investors are weighing the possibility of further dilution or a delisting risk, both of which add to the downside pressure.
Market Context and Trading Activity
The move on Monday follows a dramatic single-session collapse last Friday, when MDXH plunged from about $0.60 to close near $0.21 on volume that was many multiples of its daily average, reflecting heavy institutional repositioning after the guidance withdrawal. Monday's continued decline suggests the market is still repricing the stock in the wake of the negative catalysts, with the small-cap diagnostics name diverging sharply from the broader equity market, which showed little comparable stress.
The stock's technical picture has deteriorated markedly, with shares trading well below prior support levels and all major moving averages after the multi-day breakdown.
What Comes Next for MDXH
Investors will look to the company's full third-quarter results and earnings call on November 12 for additional detail on corrective actions and any refreshed outlook. Key watchpoints include whether the sales force can be stabilized quickly, the trajectory of tissue- and liquid-based test volumes, and how management plans to address its cash runway and Nasdaq compliance. The company faces meaningful uncertainty: a failure to regain compliance with listing requirements, further guidance disruptions, or the need for additional capital could all keep pressure on the shares.
Trending AI Robots
For traders seeking to navigate volatile markets with a systematic approach, Tickeron's Trending AI Robots page highlights AI-powered trading bots across hundreds of strategies and thousands of tickers. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, and only the strongest performers under current market conditions are featured in this curated section. Explore the page to see which AI strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDXH in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2026
MDXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 19 of 24 cases where MDXH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MDXH just turned positive on November 06, 2026. Looking at past instances where MDXH's MACD turned positive, the stock continued to rise in 24 of 31 cases over the following month. The odds of a continued upward trend are 77%.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXH advanced for three days, in 96 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXH as a result. In 36 of 50 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
MDXH moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MDXH entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.641) is normal, around the industry mean (67.298). P/E Ratio (0.000) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. MDXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement